Simon Glairy has spent his career at the intersection of technology and risk, helping insurance giants navigate the murky waters of healthcare billing. With years of experience in AI-driven fraud detection, he has seen schemes evolve from simple upcoding to sophisticated, multi-billion-dollar product-based operations that bypass traditional safeguards. We sat down with him to discuss the massive “allograft” scandal that recently rocked the industry, revealing how a specialized wound care product became the centerpiece of a $6.5 billion fraud takedown. This conversation explores the shift from Medicare-focused enforcement to the hidden liabilities sitting in commercial healthcare plans, the specific technological gaps that allow these schemes to flourish, and why the current audit processes are failing self-funded employers. We also dive into the terrifying speed at which these scams operate and the forensic evidence that finally brought down the leaders of this criminal enterprise.
The data coming out of the federal investigation into skin substitute billing is staggering, showing a jump from $256 million in 2019 to over $10 billion by 2024. How does a single product category expand forty-fold in just five years without triggering immediate shutdowns?
It is a combination of systemic blindness and the sheer audacity of the perpetrators. You have to realize that while the spending increased by nearly 40 times, the actual patient volume only doubled, which creates a mathematical impossibility in any legitimate clinical setting. The fraudsters took advantage of a distorted pricing structure where Medicare reimbursed these bioengineered human placental tissues at rates as high as $2,000 per square centimeter. This created a massive incentive for clinics to over-apply the product or bill for sizes that were never actually used on the patient. The Office of Inspector General’s 2025 report was titled with an almost exhausted tone, noting that these payment trends raised major concerns about fraud, waste, and abuse. It took a dedicated DOJ Data Analytics Team to finally pull the thread, but by then, the financial damage was already in the billions, proving that our current monitoring systems are often looking at the wrong signals.
We often hear about these cases as “Medicare fraud,” but the Apex Medical case suggests commercial insurers are just as exposed. What does the $1.2 billion in false claims from that specific case tell us about the risk to private and employer-funded plans?
The Apex case is a chilling reminder that private health plans are the “silent” victims in these federal headlines. When Alexandra Gehrke was sentenced to over 15 years and Jeffrey King to 14 years, the news focused on the $960 million billed to federal programs like Medicare and TRICARE. However, that leaves hundreds of millions of dollars that were funneled directly out of commercial insurance programs. These schemes are designed to be “payer agnostic,” meaning the fraudsters don’t care if the check comes from the government or a private employer’s self-funded plan. In the Kontos and Kupetz case, the DOJ explicitly stated that false claims were submitted to commercial insurers right alongside federal ones. Because private plans often lack the centralized data-crunching power of the federal government, they are likely sitting on mountains of paid claims that they don’t even realize are fraudulent.
If the federal government has such a massive data analytics advantage, why are self-funded employer plans and their third-party administrators still so vulnerable to these wound care schemes?
Self-funded plans are essentially bringing a knife to a gunfight because their infrastructure is built to catch old-school fraud like duplicate billing or simple upcoding. They rely on third-party administrators (TPAs) who are great at spotting if a doctor bills for the same office visit twice, but they aren’t looking for a coordinated, national spike in a niche product category like amniotic allografts. These schemes use inflated average sales prices and sham invoices to hide the fact that the provider is paying one price and billing an astronomical markup. In the Yukee indictment, investigators found an email that laid it bare: “invoice price 1600 charge 3900.” Most commercial plans simply don’t have the clinical audit processes to interrogate whether a mobile wound care clinic is actually using $1 million worth of product on a single patient, which is exactly what was happening in these schemes.
The investigation highlighted a specific “credentialing gap” involving nurse practitioners and mobile clinics. How does this shift in who provides the care change the way insurance companies need to look at risk?
The shift toward nurse practitioners (NPs) having full prescribing and billing authority has created a massive loophole that criminals are now sprinting through. In the Gehrke-King scheme, the entire operation functioned through nursing licenses because the fraudsters knew that most group benefits detection systems are calibrated to watch physician billing patterns. A mobile NP-operated clinic can move from one post-acute care facility to another, generating millions in billing without ever having a fixed brick-and-mortar location that would trigger a traditional red flag. This “mobile” nature makes it incredibly difficult to verify if the treatment even took place. Furthermore, we are seeing a trend where healthcare fraud is becoming faster and cheaper to execute, now costing roughly $105 billion annually across all payers. If your audit team is only looking at what doctors are doing in hospitals, you are missing the entire mobile frontier where this allograft fraud is thriving.
When investigators look at the electronic health records for these clinics, they often find what they call “retroactive documentation.” What does this look like in practice, and why can’t a standard audit catch it?
This is where the fraud becomes truly cynical because it involves manufacturing medical necessity after the bill has already been sent. In the Yukee case, there was an email where staff were literally told to “add conservative to all of them who don’t have,” referring to the conservative treatment prerequisites required for insurance to pay for a graft. They were essentially rewriting the history of the patient’s wound to make it look like they had tried other, cheaper options first when they hadn’t. If a plan auditor looks at those records six months later, everything looks perfect on paper because the EHR has been perfectly falsified to meet the policy requirements. This is why you cannot rely on documentation alone to find the fraud; you have to catch the statistical anomaly in the billing pattern before the money leaves the building. Once the record is “corrected” in the EHR, the fraud is effectively laundered into a legitimate-looking claim.
Medicare recently implemented a flat-rate reform of $127 per square centimeter to kill the incentive for this fraud, but commercial plans haven’t followed suit. What specific steps should a benefits manager take right now to protect their plan?
The first thing every manager needs to do is realize that the January 2026 Medicare reform didn’t stop the fraud; it just pushed it toward the payers who haven’t updated their rules yet. You need to be asking very pointed questions about any wound care provider in your network, starting with whether the clinic is mobile or fixed and if the rendering provider is a nurse practitioner or a physician. You have to look at the average billed amount per patient for these specific allograft codes; if you see a patient hitting $1 million in billing for skin substitutes, that should be an immediate “stop payment” trigger. It is also vital to investigate the referral relationships to see if the person ordering the graft has a financial tie to the clinic applying it. Without an independent verification of the acquisition cost of these products, your plan is essentially writing a blank check to anyone with a nursing license and a laptop.
What is your forecast for the future of healthcare fraud detection as these schemes become more technologically advanced?
I believe we are entering an era of “high-frequency fraud” where the window between a criminal starting a scheme and extracting millions of dollars is shrinking from years to months. As AI becomes more accessible to bad actors, they will be able to generate thousands of perfectly falsified patient records and “conservative care” histories in seconds, making it impossible for human auditors to keep up. We will see a shift toward real-time, identity-verified billing where the patient and the provider must both “check in” to a location via biometric or GPS data to prove a service actually occurred. The $19.6 billion that Medicare expects to save this year by fixing the skin substitute pricing is just one hole in the bucket; the next major wave of fraud will likely target a different high-cost biological or pharmaceutical category. If commercial payers don’t start collaborating on shared data pools to spot these national trends, they will continue to be the piggy bank for these sophisticated criminal organizations.
